RenovoRx (RNXT) announced that SCRI Oncology Partners in Nashville, TN, is now enrolling patients with locally advanced pancreatic cancer, LAPC, in the Company’s ongoing pivotal Phase III TIGeR-PaC clinical trial. SCRI Oncology Partners joins esteemed clinical sites throughout United States participating in the study. The TIGeR-PaC study is using RenovoRx’s TAMP, Trans-Arterial Micro-Perfusion, therapy platform to evaluate the Company’s first investigational drug-device combination product candidate. TAMP utilizes pressure-mediated delivery of gemcitabine to the target tumor. The study is comparing treatment with TAMP in LAPC to the current standard-of-care.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio